Effects of treadmill exercise versus Flutter® on respiratory flow and sputum properties in adults with cystic fibrosis: A randomised, controlled, cross-over trial

BMC Pulmonary Medicine

Volumn 17, Issue 1, 2017, Pages

  Dwyer, Tiffany J ^a,b,c   Zainuldin, Rahizan ^a,d,e   Daviskas, Evangelia ^b   Bye, Peter T P ^b,c   Alison, Jennifer A ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NG TENG FONG GENERAL HOSPITAL   (Singapore)

^e SINGAPORE INSTITUTE OF TECHNOLOGY   (Singapore)

Author keywords

Airway clearance; Cystic fibrosis; Exercise; Flutter ; Oscillating PEP; Physiotherapy; Sputum

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG CLEARANCE; LUNG CONGESTION; MALE; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY AIRFLOW; RESPIRATORY THERAPEUTIC DEVICE; SPUTUM; SPUTUM EXPECTORATION; SPUTUM HYDRATION; SPUTUM MECHANICAL IMPEDANCE; THERAPY EFFECT; TREADMILL EXERCISE; TREATMENT DURATION; CHEST WALL OSCILLATION; EXERCISE TEST; KINESIOTHERAPY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; YOUNG ADULT;

ADULT; AUSTRALIA; CHEST WALL OSCILLATION; CROSS-OVER STUDIES; CYSTIC FIBROSIS; EXERCISE TEST; EXERCISE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; SPUTUM; YOUNG ADULT;

EID: 85009997611     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0360-8     Document Type: Article

References (39)

1. Matsui H, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005-15.
2. Robinson M, Bye PTB. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol. 2002;33(4):293-306.
3. Dodd ME, Prasad SA. Physiotherapy management of cystic fibrosis. Chron Respir Dis. 2005;2(3):139-49.
4. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91-6.
5. Radtke T, et al. Physical exercise training for cystic fibrosis. Cochrane Database Syst Rev. 2015;6, CD002768.
6. Kim CS, Iglesias AJ, Sackner MA. Mucus clearance by two-phase gas-liquid flow mechanism: Asymmetric periodic flow model. J Appl Physiol. 1987;62(3):959-71.
7. Olseni L, Lannefors L, van der Schans CP. Airway-clearance techniques individually tailored to each patient, in Therapy for mucus-clearance disorders. Rubin BK and van der Schans CP, Editors. Therapy for mucus-clearance disorders. New York: Marcel Dekker, Inc; 2004. p. 413-431.
8. King M. Role of mucus viscoelasticity in clearance by cough. Eur J Respir Dis Suppl. 1987;153:165-72.
9. Button B, Boucher RC, University of North Carolina Virtual Lung Group. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol. 2008;163(1-3):189-201.
10. Button B, Picher M, Boucher RC. Differential effects of cyclic and constant stress on ATP release and mucociliary transport by human airway epithelia. J Physiol. 2007;580(2):577-92.
11. Hebestreit A, et al. Exercise inhibits epithelial sodium channels in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001;164(3):443-6.
12. Schmitt L, et al. Exercise reduces airway sodium ion reabsorption in cystic fibrosis but not in exercise asthma. Eur Respir J. 2011;37(2):342-8.
13. Wheatley CM, et al. Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis. Respir Med. 2015;109(8):1001-11.
14. Mellins RB. Pulmonary physiotherapy in the pediatric age group. Am Rev Respir Dis. 1974;110(6 Pt 2):137-42.
15. Dwyer TJ, et al. Effects of exercise on respiratory flow and sputum properties in cystic fibrosis. Chest. 2011;139(4):870-7.
16. Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev. 2014;7, CD006842.
17. McCarren B, Alison JA. Physiological effects of vibration in subjects with cystic fibrosis. Eur Respir J. 2006;27(6):1204-9.
18. App EM, et al. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage. Chest. 1998;114(1):171-7.
19. Fuchs HJ, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-42.
20. Miller MR, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-38.
21. Wanger J, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511-22.
22. Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. U S Armed Forces Med J. 1959;10(6):675-88.
23. Hebestreit H, et al. Statement on Exercise Testing in Cystic Fibrosis. Respiration. 2015;90(4):332-51.
24. Pryor J. The forced expiration technique, in Respiratory Care. Pryor J, Editor. Respiratory care. Edinburgh: Churchill Livingstone 1991. p. 79-100.
25. American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription. 9th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2014.
26. Konstan MW, Stern RC, Doershuk CF. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr. 1994;124(5 Pt 1):689-93.
27. Daviskas E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology. 2007;12(5):683-91.
28. Daviskas E, et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest. 2010;137(4):861-8.
29. Goldman HI, Becklake MR. Respiratory function tests; normal values at median altitudes and the prediction of normal results. Am Rev Tuberc. 1959;79(4):457-67.
30. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis. 1971;103(1):57-67.
31. Drinkwater BL, Horvath SM, Wells CL. Aerobic power of females, ages 10 to 68. J Gerontol. 1975;30(4):385-94.
32. Froelicher Jr VF, Allen M, Lancaster MC. Maximal treadmill testing of normal USAF aircrewmen. Aerosp Med. 1974;45(3):310-5.
33. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81.
34. Mahler DA, et al. Continuous measurement of breathlessness during exercise: validity, reliability, and responsiveness. J Appl Physiol. 2001;90(6):2188-96.
35. Alves LA, Pitta F, Brunetto AF. Performance analysis of the Flutter VRP1 under different flows and angles. Respir Care. 2008;53(3):316-23.
36. Brooks D, et al. The flutter device and expiratory pressures. J Cardiopulm Rehabil. 2002;22(1):53-7.
37. Alsuwaidan S, et al. Effect of exercise on the nasal transmucosal potential difference in patients with cystic fibrosis and normal subjects. Thorax. 1994;49(12):1249-50.
38. Robinson M, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J. 1999;14(3):678-85.
39. Nolan SJ, et al. Inhaled mannitol for cystic fibrosis. Cochrane Database Syst Rev. 2015;10, CD008649.